In vivo carcinogenicity testing is an expensive and time-consuming process, and as a result, only a relatively small fraction of new and existing chemicals has been tested in this manner. Therefore, the development and validation of alternative approaches is desirable. We previously developed a mammalian in vitro assay for genotoxicity based on the ability of cells to increase their level of the tumor-suppressor protein p53 in response to DNA damage. Cultured (11, 16, 17) or by initiating a cell's apoptotic pathway (18) (19) (20) (21) .
hbp://ehpnetl.niebs.ni.gov/ldocs/l999/107p805-812duerksen-hughes/abstracst.bnl Because society has made human health and safety an important consideration, considerable resources have been and are being expended in efforts to identify and classify human carcinogens. Unfortunately, methods currently used, such as the Ames test (1) and in vivo animal testing, suffer from several shortcomings. These include the need to extrapolate from prokaryotes to humans (Ames test) and the need to extrapolate from rodents to humans, the high cost, and the long period before results are known (in vivo animal testing). With all current methods there is also limited predictivity, both when examining the agreement of various methods with each other (2-6) and when applying laboratory results to actual human populations.
To aid in the development and validation of improved ways to predict the carcinogenicity of compounds, the National Institute of Environmental Health Sciences (NIEHS; Research Triangle Park, NC) initiated the predictive toxicology evaluation project (PTE). This project listed two sets of chemicals undergoing in vivo carcinogenicity testing; the first set of 44 chemicals was listed in 1990 (PTE1) and the second set of 30 chemicals in 1994 (PTE2) (7, 8) .
Researchers were invited to submit predictions regarding the ability of these chemicals to induce carcinogenesis in rodents, and the predictions and actual in vivo results were to be compared when the animal results became available. The results from PTE1 provided information regarding the features of chemicals most predictive of their ability to act as carcinogens, and the results from PTE2 will add to this dataset once all of the in vivo results are available for comparison with the predictions.
We previously developed a novel method for assessing the genotoxicity of substances that is simple, rapid, and cost-effective. This method is based on the biologic response of mammalian cells in culture to agents that damage their DNA (9) . This assay is based on the well-documented observation that the cellular level of a tumor-suppressor protein called p53 increases following DNA damage (10) (11) (12) (13) (14) (15) , primarily because of an increase in the stability of the protein and a resulting decrease in its rate of proteolysis (9, 10) . The p53 then acts to prevent replication of damaged DNA, either by causing the cell to undergo a reversible growth arrest (11, 16, 17) or by initiating a cell's apoptotic pathway (18) (19) (20) (21) .
The assay itself is simple (9) . Cultured mammalian cells (NCTC 929) are treated with various doses of the test agent, and at specified time points following treatment, the cells are harvested and lysed. The level of p53 in the lysates is measured by p53 enzymelinked immunosorbent assay (ELISA) and/or Western blot analysis, and compared to the level in untreated cells.
Our previous work (9) indicated that both Western blot and ELISA analyses yielded similar results. Therefore, our current work focused on the more quantitative ELISA assay. We also found that the NCTC 929 cell line was a useful model system. NCTC 929 cells were initially selected because previously published results (10) indicated that their levels of p53 rise following genotoxin treatment. We verified this, and found in addition that p53 in these cells can be immunoprecipitated by a monoclonal antibody specific for wild-type p53. We also found that the level of p53 in these cells rises significantly following treatment with indirect genotoxins such as aflatoxin BI and 2- acetylaminofluorene, indicating that they possess significant amounts of the metabolic activities necessary for biotransformation (9. To determine the ability of this assay to predict carcinogenicity in rodents and to compare its performance with other proposed alternatives, we subjected 25 Each chemical was tested, at the several dosages and at the two time points, between two and four times. In some cases, specific doses were repeated in additional trials.
To ensure that the p53 response of these cells to both direct-and indirect-acting genotoxic chemicals remained intact and relatively constant during these experiments, cultures of NCTC 929 cells from passages currently in use were periodically treated with known direct (N-methyl-N'-nitronitrosoguanidine) and indirect (mitomycin C) genotoxins (9) to verify that the cells could adequately respond to both types of chemicals. We found that the cellular response to both direct-and indirect-acting chemicals was stable throughout and beyond the course of these experiments.
Cell lysis andp53 ELISA. Cells were harvested, lysed, and analyzed for their protein concentration by the BCA assay (Pierce, Rockford, IL) and for their p53 levels by ELISA, as described previously (9) . Briefly, cells were removed from the plate by trypsinization, concentrated by centrifugation, and suspended in lysis buffer. After lysis, lysates were stored at -80°C for no more than 1 Summary. Table 2 shows the summary data for the substances that we tested as well _ as previously reported results from the 20 50
Salmonella and SHE assays (22) . It Tetrahydrofuiran. A 10-mg/mL stock of tetrahydrofuran was prepared in DMSO, and cells were treated with doses of 1, 5, 10, 20, 25, 50, and 100 ,ug/mL. Cells treated with tetrahydrofiran did not display cytotoxicity at any of the times or doses tested, and did not induce p53 at any of the times or doses tested. Tetrahydrofuran is therefore dassified as negative. The Salmonella and SHE results were negative. In animal studies, some evidence for carcinogenicity was found in male rats, no evidence in female rats and male mice, and clear evidence in female mice.
Discussion
The purpose of this study was to determine the ability of the newly developed p53-induction assay to identify genotoxic substances and to predict carcinogenicity in rodents. To this end, we subjected 25 of the 30 PTE2 substances to this test. Five substances strongly and reproducibly increased cellular p53 levels and therefore were dassified as positive, three substances increased cellular p53 levels, but to a less significant extent and therefore were identified as possibly positive, and seventeen substances did not significantly increase cellular p53 levels and were therefore classified as negative.
Five of the PTE2 substances were not tested. As currently configured, our assay system is capable of testing solid or liquid substances that can be dissolved in culture media to the required concentrations and which will remain in solution for several hr at 37°C. Anthraquinone, molybdenum trioxide, and vanadium pentoxide were not tested because of the limited solubility of these substances in water, culture media, and DMSO.
It may be possible in the future to identify conditions that will allow us to deliver the substances to the cells at the required concentrations. Isobutene is a gas at room temperature and was not tested; it may be possible in the future to set up a delivery system that would deliver a constant concentration of the gas to cells in culture. Chloroprene was not tested because it cannot be shipped. To distinguish between the two, it may be helpful to perform additional trials of these substances to confirm the reproducibility of the observed increases. The strength of this p53-induction assay is expected to be in identifying genotoxic compounds, of which this PTE2 group contains only a few. We therefore drew comparisons between results from the p53-induction assay and the in vivo results for both the entire set of tested compounds and separately for the genotoxic substances. Figure 4 summarizes the comparisons between the Salmonel4, p53 induction, SHE, and in vivo test results. Figure 4A compares This accounts for the differences in the totals for the induded analyses. Also, for the "any of the three" analysis, a chemical is scored as in vitro positive if any of the three tests (Salmonella, p53 induction, or SHE) gave a positive result. By these criteria, the Salmonella test gave a concordance with the in vivo test results of 32%, the p53-induction assay a concordance of 40%, the "any of the three" results a concordance of 59%, and the SHE assay a concordance of 67%. Therefore, by this analysis, the SHE test yielded the highest concordance with the in vivo results, followed by the composite, then the p53 induction, and finally the Salmonella assays. These results also reflect the higher likelihood of the SHE test to produce positive results for this set of chemicals, most of which were also positive in in vivo testing.
A comparison of the result from the p53-induction assay and the in vivo results for only the genotoxic compounds in this group (those that tested positive in the Salmonella assay) shows that two substances were positive in both (cobalt sulfate heptahydrate and D&C Yellow No. 11), one substance was positive in vivo but negative in the p53-induction assay (primaclone), and one substance was negative in both assays (1-chloro-2-propanol). Of this limited number of genotoxic compounds present in the PTE2 list, the p53-induction assay has a concordance of75%.
Because the primary motivation in performing these types of studies is the protection of human health, transspecies carcinogens may be of greater concern than single-species carcinogens. Figure 4B compares the in vivo test results for trans-species carcinogens with each of the three in vitro protocols separately, and with a combination of predictions from the three in vitro protocols. In this analysis, chemicals were classified as in vivo positives only if some or clear evidence of carcinogenicity was obtained in both tested species; otherwise, the analysis was as described for Figure 4A . By these criteria, the "any of the three" results gave a concordance of 35%, the Salmonella test a concordance of 50%, the SHE assay a concordance of 53%, and the p53-induction assay a concordance of 56%. Therefore, by this analysis, the p53-induction assay yielded the highest concordance with the in vivo results, followed by the SHE analysis, then the Salmonella, and finally the composite assays. Because fewer of the in vivo results are classified as positive by the transspecies criteria, the concordance of the two assays less likely to test positive for this set of chemicals (Salmonella and p53 induction) with the in vivo test results was improved, and the concordance of the two data sets more likely to test positive for this set of chemicals (SHE and "any of the three") decreased.
A comparison of the p53-induction assay results and the transspecies in vivo results for only the genotoxic compounds in this group (those that tested positive in the Salmonella assay) shows that one substance was positive in both assays (cobalt sulfate heptahydrate) and two substances were negative in both assays (1-chloro-2-propanol and primaclone). Of this limited number of genotoxic compounds present in the PTE2 list, the p53-induction assay has a concordance with the in vivo results of 100%. Figure 4C compares results from the three in vitro assays with each other. In this analysis, only those chemicals for which both listed assays have been reported are induded. The concordance of Salmonella and SHE assays is 44%, that of the p53-induction and SHE assays is 48%, and the p53-induction and Salmonella assays is 63%, indicating that of the three, the p53 induction and the Salmonella assays are the most like each other, although still significantly different. t in the in vivo protocol is that they could cause increases in cellular p53 levels by a mechanism independent of DNA damage (23) . For example, a substance that could block proteosome function would be expected to increase cellular p53 (24, 25 We have previously shown that the increase in p53 is transient with respect to time and is maximal at certain substancespecific doses, and that a higher dose does not necessarily lead to a higher level of cellular p53. In this study, only a limited number of times and doses could be tested. Based on our previous work (9), direct-acting genotoxic chemicals induced p53 at early times (2-8 hr), whereas indirect-acting genotoxic chemicals induced p53 at later times (12-24 hr ). Hence, we tested each of these 25 PTE2 chemicals at both early (6 hr) and late (17 hr) time points in an attempt to detect both direct and indirect genotoxins. We found that one chemical exerted significant effects at more doses at the early time point than at the latter (D&C Yellow No. 11), and that others showed an effect at only the latter time point (citral, oxymetholone, t-butylhydroquinone; compare Figure 2 and Figure  1) . It is possible, however, that a substance capable of weakly inducing p53 could exert its maximal effect at a time other than those tested, and that any induction seen at the tested times was not statistically significant.
Previously tested genotoxins yielded maximal induction at doses between 1 and 100 pg/mL; therefore, for each of the 25 substances analyzed, we tested several doses between 0.5 and 100 gg/mL. We found that most of the chemicals that tested positive did so only at one or a few of the tested doses, suggesting that the dose range at which an effect can be observed may be rather narrow. For a number of the substances, the higher doses (25, 50 , and 100 j.g/mL) induced extensive cytotoxicity, compromising the validity of the p53 assay at those dosages. It is possible that a substance testing negative in our assay would have tested positive at some other untested dose. Our results were analyzed with the Scheffe S-test, which is a relatively conservative post hoc test for differences.
The expected strength of this p53-induction assay is in the identification of genotoxic compounds. There were few of these compounds in this PTE2 group, and with these few compounds, the p53-induction assay did an excellent job of identifying them. The most likely explanation for the inability of this assay to identify many of the carcinogenic compounds in this group is that they are epigenetic substances that cause cancer by nongenotoxic mechanisms. Additionally, factors such as absorption, distribution, metabolism, and excretion, which operate in whole animals but do not operate in in vitro test systems, could play a role.
It has been suggested by Ashby and Tennant (26) that carcinogenicity may result from a specific interaction between the chemical and the tissue rather than it being an intrinsic and unique property of the chemical; therefore, it may well be that no one chemical feature or assay will provide the predictivity desired. It may therefore be helpful to add this new set of information to that considered when evaluating the carcinogenic potential of substances. For example, the results of the p53-induction assay could be considered as an input in the induction of rules for predicting chemical carcinogenicity in rodents (27) .
